207 related articles for article (PubMed ID: 37324940)
1. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
[TBL] [Abstract][Full Text] [Related]
2. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
3. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
[TBL] [Abstract][Full Text] [Related]
5. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Okamoto K; Miyoshi K; Murawaki Y
PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
[TBL] [Abstract][Full Text] [Related]
6. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
7. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
9. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptotic cell death of cholangiocarcinoma cells by tiliacorinine from Tiliacora triandra: A mechanistic insight.
Detarya M; Mahalapbutr P; Waenphimai O; Kidoikhammouan S; Janeklang S; Sawanyawisuth K; Vaeteewoottacharn K; Seubwai W; Saengboonmee C; Thothaisong T; Pabuprapap W; Suksamrarn A; Wongkham S
Biochim Biophys Acta Gen Subj; 2023 Dec; 1867(12):130486. PubMed ID: 37813201
[TBL] [Abstract][Full Text] [Related]
11. Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis.
Thamrongwaranggoon U; Detarya M; Seubwai W; Saengboonmee C; Hino S; Koga T; Nakao M; Wongkham S
Life Sci; 2022 Aug; 302():120648. PubMed ID: 35598658
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
13.
Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
[No Abstract] [Full Text] [Related]
14. Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy.
Yeh CN; Pang ST; Wu RC; Chen TW; Jan YY; Chen MF
Oncol Rep; 2009 Jan; 21(1):49-56. PubMed ID: 19082442
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
Bafna S; Kaur S; Momi N; Batra SK
Br J Cancer; 2009 Oct; 101(7):1155-61. PubMed ID: 19738614
[TBL] [Abstract][Full Text] [Related]
17. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
18. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
[TBL] [Abstract][Full Text] [Related]
19. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
20. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]